Clearmind Medicine Inc. (CMND)
NASDAQ: CMND · Real-Time Price · USD
0.9665
-0.0105 (-1.07%)
At close: May 9, 2025, 4:00 PM
0.9789
+0.0124 (1.28%)
After-hours: May 9, 2025, 7:58 PM EDT

Clearmind Medicine Cash Flow Statement

Millions USD. Fiscal year is Nov - Oct.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Jan '25 Oct '24 Oct '23 Oct '22 Oct '21 Oct '20 2017 - 2019
Net Income
-4.96-5.25-8.62-6.89-3-0.31
Upgrade
Depreciation & Amortization
0.050.050.060.080.010.14
Upgrade
Loss (Gain) From Sale of Investments
0.140.070.110.31--
Upgrade
Stock-Based Compensation
1.230.880.371.210.68-
Upgrade
Other Operating Activities
-1.11-0.482.760.33--
Upgrade
Change in Accounts Receivable
-0.060.06-0.150.02-0.13-0
Upgrade
Change in Accounts Payable
0.11-0.2-0.620.910.28-0.01
Upgrade
Change in Other Net Operating Assets
-0.080-0.190.3-0.13-0.02
Upgrade
Operating Cash Flow
-4.66-4.86-6.3-3.72-2.29-0.2
Upgrade
Capital Expenditures
----0.01-0.03-0.01
Upgrade
Sale (Purchase) of Intangibles
-----0.16-
Upgrade
Investment in Securities
-0.19-0.27----
Upgrade
Other Investing Activities
0.020.03-0.03--0.020
Upgrade
Investing Cash Flow
-0.17-0.24-0.03-0.01-0.2-0
Upgrade
Long-Term Debt Repaid
--0.04-0.04-0.07--
Upgrade
Net Debt Issued (Repaid)
-0.05-0.04-0.04-0.07--
Upgrade
Issuance of Common Stock
1.396.311.710.585.930.45
Upgrade
Financing Cash Flow
1.346.2511.660.515.930.45
Upgrade
Foreign Exchange Rate Adjustments
-0.02-0.01-0.04-0.02--
Upgrade
Net Cash Flow
-3.51.155.3-3.243.440.25
Upgrade
Free Cash Flow
-4.66-4.86-6.3-3.73-2.31-0.21
Upgrade
Free Cash Flow Per Share
-1.21-1.57-31.12-86.08-74.84-11.38
Upgrade
Cash Interest Paid
0.010.0100.01--
Upgrade
Cash Income Tax Paid
0.280.310.01---
Upgrade
Levered Free Cash Flow
-3.34-3.13-0.62-0.88-1.33-0.09
Upgrade
Unlevered Free Cash Flow
-3.31-3.11-0.61-0.87-1.33-0.09
Upgrade
Change in Net Working Capital
1.30.82-2.91-1.76-0.020.02
Upgrade
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q